Neurological events related to influenza A (H1N1) pdm09.
Autor(es): Cárdenas Graciela; Soto-Hernández José Luis; Díaz-Alba Alexandra; Ugalde Yair; Mérida-Puga Jorge; Rosetti Marcos; Sciutto Edda
Resumo: To review neurological complications after the influenza A (H1N1) pdm09, highlighting the clinical differences between patients with post-vaccine or viral infection. A search on Medline, Ovid, EMBASE, and PubMed databases using the keywords "neurological complications of Influenza AH1N1" or "post-vaccine Influenza AH1N1." Only papers written in English, Spanish, German, French, Portuguese, and Italian published from March 2009 to December 2012 were included. We included 104 articles presenting a total of 1636 patient cases. In addition, two cases of influenza vaccine-related neurological events from our neurological care center, arising during the period of study, were also included. Demographic data and clinical diagnosis of neurological complications and outcomes: death, neurological sequelae or recovery after influenza A (H1N1) pdm09 vaccine or infection. The retrieved cases were divided into two groups: the postvaccination group, with 287 patients, and the viral infection group, with 1349 patients. Most patients in the first group were adults. The main neurological complications were Guillain-Barre syndrome (GBS) or polyneuropathy (125), and seizures (23). All patients survived. Pediatric patients were predominant in the viral infection group. In this group, 60 patients (4.7%) died and 52 (30.1%) developed permanent sequelae. A wide spectrum of neurological complications was observed. Fatal cases and severe, permanent, neurological sequelae were observed in the infection group only. Clinical outcome was more favorable in the post-vaccination group. In this context, the relevance of an accurate neurological evaluation is demonstrated for all suspicious cases, as well as the need of an appropriate long-term clinical and imaging follow-up of infection and post-vaccination events related to influenza A (H1N1) pdm09, to clearly estimate the magnitude of neurological complications leading to permanent disability.
Imprenta: Influenza and other Respiratory Viruses, v. 8, n. 3, p. 339-346, 2014
Identificador do objeto digital: 10.1111/irv.12241
Descritores: Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Viral infections ; Guillain-Barre Syndrome - Virus ; Guillain-Barre Syndrome - Vaccine ; Guillain-Barre Syndrome - Epidemiology
Data de publicação: 2014
